Lonza Completes Expansion of New Drug Product Services Facility in Basel (CH)
Lonza recently announced it has enhanced its drug product services offering by adding a new facility for quality control and bioanalytics at its DPS site in Basel (CH) to support Lonza’s global DP capacity increase. It will enable Lonza to accelerate product delivery, which is crucial for enabling its customers to progress through clinical development and commercialization.
The planned expansion includes 6000 m2 of state-of-the-art laboratories and office space to support market demand for early and late-stage clinical and commercial DP QC. The new facility allows DPS to double its capacity for the development and testing of parenteral dosage forms and strengthens existing DP capabilities offered from the Stücki Technology Park in Basel (CH).
Peter Droc, Head of Drug Product Services, Lonza, said “Expanding Lonza’s drug product capacity is a key enabler of our wider Biologics strategy to offer drug developers a seamless solution across modalities, from early development to drug substance and drug product manufacture. With the demand for drug product manufacturing continuing to increase, this new bioanalytics and QC facility will enable us to provide our customers with crucial manufacturing services for the delivery of life-saving medicines.”
Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.
Our business is structured to meet our customers’ complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 893 million in Half-Year 2024. Find out more at www.lonza.com.
Total Page Views: 77
